Merrimack Pharmaceuticals Net Income

Merrimack Pharmaceuticals (MACK) currently reports a net income of $-25M as of March 2024. That compares with $-1.4M in the prior-year period — down 1695.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Merrimack Pharmaceuticals's net income history and peer comparisons.

Merrimack Pharmaceuticals's net income decreased from $-1.4M to $-25M — a 1695.2% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Merrimack Pharmaceuticals's net income of $-25M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Merrimack Pharmaceuticals reported $-25M in net income as of March 2024. That compares with $-1.4M in the prior-year period — down 1695.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-25M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Merrimack Pharmaceuticals, and consider following MACK for alerts when major investors trade the stock.